(Total Views: 497)
Posted On: 11/19/2020 9:47:48 PM
Post# of 36566
Another one -
https://www.bioworld.com/articles/500404-othe...ov-19-2020
Generex Biotechnology Corp., of Miramar, Fla., said it signed a worldwide licensing and development agreement with a consortium of partners in China to utilize the Ii-Key vaccine platform technology from Generex subsidiary Nugenerex Immuno-Oncology for developing a vaccine against the G4 EA H1N1 swine influenza emerging in China. Generex will receive an up-front fee of $2.5 million to initiate vaccine development work to identify swine flu epitopes. The partnership will provide full funding for product development, regulatory approval and commercialization worldwide. Generex originally developed the Ii-Key-H5 vaccine in 2003 in response to avian influenza.
https://www.bioworld.com/articles/500404-othe...ov-19-2020
Generex Biotechnology Corp., of Miramar, Fla., said it signed a worldwide licensing and development agreement with a consortium of partners in China to utilize the Ii-Key vaccine platform technology from Generex subsidiary Nugenerex Immuno-Oncology for developing a vaccine against the G4 EA H1N1 swine influenza emerging in China. Generex will receive an up-front fee of $2.5 million to initiate vaccine development work to identify swine flu epitopes. The partnership will provide full funding for product development, regulatory approval and commercialization worldwide. Generex originally developed the Ii-Key-H5 vaccine in 2003 in response to avian influenza.
(1)
(0)
